Arkolith/Insider Trading/EBS/Form 4

Katkin Keith

DirectorEmergent BioSolutions Inc. (EBS) · full profile →Form 4 · filed May 4, 2026
Net Selling
Open-Market Buys
$0
Open-Market Sells
$128K
Net Open-Market Flow
-$128K
Transactions
3
2 non-derivative · 1 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
Apr 30, 2026Grant(A)25K—$0112K
Apr 30, 2026Sell(S)15K$8.28$128K96K

Derivative Transactions (Table II)

DateActionSharesPriceValueOwned After
Apr 30, 2026Grant(A)11K—$011K

Transaction Codes

A
Grant / award
S
Open-market sale

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0001314596-26-000002) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

View original filing on SEC.govRaw Form 4 XML